Skip to main content Accessibility help
×
Home
  • Print publication year: 2012
  • Online publication date: August 2012

3 - Evidence-based pharmacotherapy of bipolar disorder

References

Allen MH, Hirschfeld RM, Wozniak PJ et al. (2006). Linear relationship of valproate serum concentration to response and optimal serum levels for acute mania. American Journal of Psychiatry 163 (2), 272–275.
Amrollahi Z, Rezaei F, Salehi B et al. (2011). Double-blind, randomized, placebo-controlled 6-week study on the efficacy and safety of the tamoxifen adjunctive to lithium in acute bipolar mania. Journal of Affective Disorders 129 (1–3), 327–331.
Angst J (1995). [Epidemiology of the bipolar spectrum]. Encephale 21(Spec No. 6), 37–42.
Beynon S, Soares-Weiser K, Woolacott N et al. (2008). Psychosocial interventions for the prevention of relapse in bipolar disorder: systematic review of controlled trials. British Journal of Psychiatry 192, 5–11.
Beynon S, Soares-Weiser K, Woolacott N et al. (2009). Pharmacological interventions for the prevention of relapse in bipolar disorder: a systematic review of controlled trials. Journal of Psychopharmacology 23, 574–591.
Bhagwagar Z, Goodwin GM (2002). Role of mood stabilizers in bipolar disorder. Expert Reviews in Neurotherapeutics 2, 239–248.
Bond DJ, Lam RW, Yatham LN (2009). Divalproex sodium versus placebo in the treatment of acute bipolar depression: A systematic review and meta-analysis. Journal of Affective Disorders 124, 228–234.
Bowden CL, Calabrese JR, McElroy SL et al. (2000). A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Archives of General Psychiatry 57, 481–489.
Bowden CL, Calabrese JR, Sachs G et al. (2003) A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Archives of General Psychiatry 60, 392–400.
Bowden CL, Mosolov S, Hranov L et al. (2010) Efficacy of valproate versus lithium in mania or mixed mania: a randomized, open 12-week trial. International Clinical Psychopharmacology 25(2), 60–67.
Bowden CL, Swann AC, Calabrese JR et al. (2006). A randomized, placebo-controlled, multicenter study of divalproex sodium extended release in the treatment of acute mania. Journal of Clinical Psychiatry 67,1501–1510.
Calabrese JR, Bowden CL, Sachs G et al. (2003). A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. Journal of Clinical Psychiatry 64, 1013–1024.
Calabrese JR, Shelton MD, Rapport DJ et al. (2005). A 20-month, double-blind, maintenance trial of lithium versus divalproex in rapid-cycling bipolar disorder. American Journal of Psychiatry 162, 2152–2161.
Calabrese JR, Suppes T, Bowden CL et al. (2000). A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study Group. Journal of Clinical Psychiatry 61, 841–850.
Cipriani A, Pretty H, Hawton K, Geddes JR (2005). Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: a systematic review of randomized trials. American Journal of Psychiatry 162, 1805–1819.
Cipriani A, Rendell J, Geddes JR (2010). Olanzapine in the long-term treatment of bipolar disorder: a systematic review and meta-analysis. Journal of Psychopharmacology 24,1729–1738.
Clement S, Singh SP, Burns T (2003). Status of bipolar disorder research. Bibliometric study. British Journal of Psychiatry 182, 148–152.
Frye MA, Ketter TA, Kimbrell TA et al. (2000). A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. Journal of Clinical Psychopharmacology 20, 607–614.
Gao K, Kemp DE, Ganocy SJ et al. (2008). Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. Journal of Clinical Psychopharmacology 28, 203–209.
Geddes J, Freemantle N, Harrison P, Bebbington P (2000). Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. British Medical Journal 321(7273), 1371–1376.
Geddes JR, Burgess S, Hawton K et al. (2004). Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. American Journal of Psychiatry 161, 217–222.
Geddes JR, Calabrese JR, Goodwin GM (2009). Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. British Journal of Psychiatry 194, 4–9.
Geddes JR, Goodwin GM, Rendell J et al. (2010). Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet 375(9712), 385–395.
Gijsman HJ, Geddes JR, Rendell JM et al. (2004). Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. American Journal of Psychiatry 161, 1537–1547.
Goodwin, GM (1994). Recurrence of mania after lithium withdrawal. Implications for the use of lithium in the treatment of bipolar affective disorder. British Journal of Psychiatry 164, 149–152.
Goodwin GM (2009). Evidence-based guidelines for treating bipolar disorder: revised second edition – recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology 23, 346–388.
Goodwin GM, Bowden CL, Calabrese JR et al. (2004). A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. Journal of Clinical Psychiatry 65, 432–441.
Greil W, Ludwig-Mayerhofer W, Erazo N et al. (1997). Lithium versus carbamazepine in the maintenance treatment of bipolar disorders – a randomised study. Journal of Affective Disorders 43, 151–161.
Grunze H, Kasper S, Goodwin G et al. (2004). The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders, part III: maintenance treatment. World Journal of Biological Psychiatry 5(3), 120–135.
Hartong EG, Moleman P, Hoogduin CA et al. (2003). Prophylactic efficacy of lithium versus carbamazepine in treatment-naive bipolar patients. Journal of Clinical Psychiatry 64, 144–151.
Hirschfeld RM, Bowden CL, Wozniak P, Collins M (2010). A randomized, placebo-controlled, multicenter study of divalproex sodium extended-release in the acute treatment of mania. Journal of Clinical Psychiatry 71, 426–432.
Jensen NH, Rodriguiz RM, Caron MG et al. (2008). N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology 33, 2303–2312.
Johnson RE, McFarland BH (1996). Lithium use and discontinuation in a health maintenance organization. American Journal of Psychiatry 153, 993–1000.
Johnstone EC, Crow TJ, Frith CD, Owens DG (1988). The Northwick Park “functional” psychosis study: diagnosis and treatment response. Lancet 2(8603), 119–125.
Judd LL, Akiskal HS, Schettler PJ et al. (2002). The long-term natural history of the weekly symptomatic status of bipolar I disorder. Archives of General Psychiatry 59, 530–537.
Keck PE Jr, Calabrese JR, McIntyre RS et al. (2007). Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. Journal of Clinical Psychiatry 68, 1480–1491.
Kessing LV, Andersen PK, Mortensen PB, Bolwig TG (1998). Recurrence in affective disorder. I. Case register study. British Journal of Psychiatry 172, 23–28.
Lopez AD, Mathers CD, Ezzati M et al. (2006). Global Burden of Disease and Risk Factors. Washington, DC: World Bank.
Macritchie K, Geddes JR, Scott J et al. (2003). Valproate for acute mood episodes in bipolar disorder. Cochrane Database of Systematic Reviews 1, CD004052.
McElroy SL, Weisler RH, Chang W et al. (2010). A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). Journal of Clinical Psychiatry 71, 163–174.
Mitchell PB, Goodwin GM, Johnson GF, Hirschfeld RM (2008). Diagnostic guidelines for bipolar depression: a probabilistic approach. Bipolar Disorders 10(1 Pt 2), 144–152.
Nierenberg AA, Sylvia LG, Leon AC et al. (2009). Lithium treatment – moderate dose use study (LiTMUS) for bipolar disorder: rationale and design. Clinical Trials 6, 637–648.
Okuma T, Yamashita I, Takahashi R et al. (1990). Comparison of the antimanic efficacy of carbamazepine and lithium carbonate by double-blind controlled study. Pharmacopsychiatry 23(3), 143–150.
Perlis RH, Welge JA, Vornik LA et al. (2006). Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials. Journal of Clinical Psychiatry 67, 509–516.
Prien RF, Caffey EM Jr, Klett CJ (1972). Comparison of lithium carbonate and chlorpromazine in the treatment of mania. Report of the Veterans Administration and National Institute of Mental Health Collaborative Study Group. Archives of General Psychiatry 26, 146–153.
Sachs GS, Grossman F, Ghaemi SN et al. (2002). Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. American Journal of Psychiatry 159, 1146–1154.
Sachs GS, Nierenberg AA, Calabrese JR et al. (2007). Effectiveness of adjunctive antidepressant treatment for bipolar depression. New England Journal of Medicine 356(17), 1711–1722.
Sachs GS, Thase ME, Otto MW et al. (2003). Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD) Biological Psychiatry 53(11), 1028–1042.
Simon NM, Otto MW, Wisniewski SR et al. (2004). Anxiety disorder comorbidity in bipolar disorder patients: data from the first 500 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) American Journal of Psychiatry 161, 2222–2229.
Smith LA, Cornelius V, Warnock A et al. (2007). Pharmacological interventions for acute bipolar mania: a systematic review of randomized placebo-controlled trials. Bipolar Disorders 9, 551–560.
Suppes T, Datto C, Minkwitz M et al. (2010). Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression. Journal of Affective Disorders 121, 106–115.
Suppes T, Hirschfeld RM, Vieta E et al. (2008). Quetiapine for the treatment of bipolar II depression: analysis of data from two randomized, double-blind, placebo- controlled studies. World Journal of Biological Psychiatry 9, 198–211.
Suppes T, Vieta E, Liu S et al. (2009). Maintenance treatment for patients with bipolar I disorder: results from a North American study of quetiapine in combination with lithium or divalproex (trial 127). American Journal of Psychiatry 166, 476–488.
Suppes T, Webb A, Paul B et al. (1999). Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania. American Journal of Psychiatry 156, 1164–1169.
Thase ME, Jonas A, Khan A et al. (2008). Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies. Journal of Clinical Psychopharmacology 28, 13–20.
Tohen M, Greil W, Calabrese JR et al. (2005). Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. American Journal of Psychiatry 162, 1281–1290.
Tohen M, Vieta E, Calabrese J et al. (2003). Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Archives of General Psychiatry 60, 1079–1088.
Tohen M, Vieta E, Goodwin GM et al. (2008). Olanzapine versus divalproex versus placebo in the treatment of mild to moderate mania: a randomized, 12-week, double-blind study. Journal of Clinical Psychiatry 69, 1776–1789.
van der Loos ML, Mulder PG, Hartong EG et al. (2009). Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial. Journal of Clinical Psychiatry 70, 223–231.
Vasudev A, Macritchie K, Watson S et al. (2008). Oxcarbazepine in the maintenance treatment of bipolar disorder. Cochrane Database of Systematic Reviews 1, CD005171.
Vieta E, Suppes T, Eggens I et al. (2008). Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). Journal of Affective Disorders 109, 251–263.
Wagner KD, Kowatch RA, Emslie GJ et al. (2006). A double-blind, randomized, placebo-controlled trial of oxcarbazepine in the treatment of bipolar disorder in children and adolescents. American Journal of Psychiatry 163, 1179–1186.
Weisler RH, Calabrese JR, Thase ME et al. (2008). Efficacy of quetiapine monotherapy for the treatment of depressive episodes in bipolar I disorder: a post hoc analysis of combined results from 2 double-blind, randomized, placebo-controlled studies. Journal of Clinical Psychiatry 69, 769–782.
Weisler RH, Hirschfeld R, Cutler AJ et al. (2006). Extended-release carbamazepine capsules as monotherapy in bipolar disorder: pooled results from two randomised, double-blind, placebo-controlled trials. CNS Drugs 20, 219–231.
Winokur G, Coryell W, Keller M et al. (1993). A prospective follow-up of patients with bipolar and primary unipolar affective disorder. Archives of General Psychiatry 50, 457–465.
Yildiz A, Guleryuz S, Ankerst DP, Ongür D, Renshaw PF. (2008). Protein kinase C inhibition in the treatment of mania: a double-blind, placebo-controlled trial of tamoxifen. Archives of General Psychiatry 65, 255–263.
Yildiz A, Vieta E, Leucht S, Baldessarini RJ (2011). Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials. Neuropsychopharmacology 36, 375–389.
Young AH, McElroy SL, Bauer M et al. (2010). A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). Journal of Clinical Psychiatry 71, 150–162.
Zarate CA Jr, Singh JB, Carlson PJ et al. (2007). Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study. Bipolar Disorder 9, 561–570.